Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia.

IF 12.9 1区医学 Q1 HEMATOLOGY

Blood Cancer Journal Pub Date : 2024-08-07 DOI:10.1038/s41408-024-01106-7

Eleanor Frost, Jonathan N Hofmann, Wen-Yi Huang, Ashley A Frazer-Abel, Kevin D Deane, Sonja I Berndt

引用次数: 0

Abstract

Impact: Immune dysregulation is thought to contribute to chronic lymphocytic leukemia (CLL) risk, but biological mechanisms are unclear. We discovered that increased serum levels of B-cell activating factor (BAFF), an important regulator of B-cell maturation, were associated with a decreased risk of CLL, even >10 years after blood draw. Our findings suggest that BAFF could be a useful biomarker to assess risk among individuals at high risk, such as those with monoclonal b-cell lymphocytosis.

Abstract Image

查看原文本刊更多论文

血清中的 B 细胞活化因子水平与慢性淋巴细胞白血病风险的降低有关。

影响：免疫失调被认为是导致慢性淋巴细胞白血病（CLL）风险的原因之一，但其生物学机制尚不清楚。我们发现，B细胞活化因子（BAFF）是B细胞成熟的一个重要调节因子，其血清水平的升高与CLL风险的降低有关，即使在抽血10年后也是如此。我们的研究结果表明，BAFF可能是评估高危人群（如单克隆B细胞淋巴细胞增多症患者）风险的有用生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Journal ONCOLOGY-

CiteScore

16.70

自引率

2.30%

发文量

153

审稿时长

>12 weeks

期刊介绍： Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.